蛋白磷酸酶2A与肿瘤发生发展关系的研究进展

doi:10.13481/j.1671-587X.20250229

Abstract

Abstract:

Protein phosphatase 2A（PP2A） is one of the major serine-threonine protein phosphatases in mammalian cells which plays an important role in regulating biological activities such as cellular mitosis and protein dephosphorylation. PP2A acts as a tumor suppressor and has been demonstrated to be genetically altered or functionally inactivated in a variety of solid cancers and leukemias， and its activity is inhibited， leading to subsequent proliferation of tumor cells. Clinical studies have shown that endogenous inhibitors such as SET， cancerous inhibitor of PP2A（CIP2A） and protein phosphatase methylesterase-1（PME-1） may reduce PP2A activity， which could be important indicators of tumor progression or recurrence. On the other hand， PP2A-activating drugs （e.g.FTY720） can restore the tumor-suppressing activity of PP2A by altering the structure of the inhibitor SET， thus effectively inhibiting tumor development. Therefore， PP2A and its inhibitors may serve as potential therapeutic targets in clinic. This article provides a comprehensive review on the mechanism of action of PP2A and its inhibitors in the pathogenesis of malignant tumor as well as their applications in oncotherapy， aiming to provide new directions for the treatment of malignant tumors.

Key words: Protein phosphatase 2A, Endogenous inhibitor, Tumor, Cancerous inhibitor of protein phosphatase 2A, Protein phosphatase methylesterase-1

CLC Number:

R730.2

Huiling ZHANG,Wenxiu GUO,Jun MENG. Research progress in relationship between protein phosphatase 2A and occurrence and development of tumor[J].Journal of Jilin University(Medicine Edition), 2025, 51(2): 534-540.

Figures/Tables 1

Tab.1

PP2A subunits and their binding proteins"

Subunit

Gene

Aliases （isoforms）

Structural

PPP2R1A

PPP2R1B

PR65α（Aα）

PR65β（Aβ）

PP2A_B

PP2A_B'

PPP2R2A

PPP2R2B

PPP2R2C

PPP2R2D

PPP2R5A

PPP2R5B

PPP2R5C

PPP2R5D

PPP2R5E

B55α，PR55α（Bα）

B55β，PR55β（Bβb）

B55γ，PR55γ1（Bγ）

B55δ，PR55δ（Bδ）

B56α，PR61α（Bα）

B56β，PR61β（Bβ）

B56γ，PR61γ（Bγ1，Bγ2，Bγ3）

B56δ，PR61δ（Bδ）

B56ε，PR61ε（Bε)

PP2A_B

″

PPP2R3A

PPP2R3B

PPP2R3C

B130，PR130（Bα1）； B72

PR72（Bα2）

PR48（Bβ1，Bβ2）

G5PR（Bγ）

PP2A_B

?

STRN，STRN3

PR110，PR93

PP2A_C

PPP2CA

PPP2CB

PP2Aα（Cα）

PP2Aβ（Cβ）

Tab.1

References 50

1	LIU X Y， XIAO W D， ZHANG Y N， et al. Reversible phosphorylation of Rpn1 regulates 26S proteasome assembly and function［J］. Proc Natl Acad Sci USA， 2020， 117（1）： 328-336.
2	DAY E K， SOSALE N G， LAZZARA M J. Cell signaling regulation by protein phosphorylation： a multivariate， heterogeneous， and context-dependent process［J］. Curr Opin Biotechnol， 2016， 40： 185-192.
3	ROLDÁN M， NOLASCO G A， ARMENGOL L， et al. Advanced optical microscopy： unveiling functional insights regarding a novel PPP2R1A variant and its unreported phenotype［J］. Int J Mol Sci， 2023， 24（18）： 13699.
4	WANG L， YIN Y L， LIU X Z， et al. Current understanding of metal ions in the pathogenesis of Alzheimer’s disease［J］. Transl Neurodegener， 2020， 9： 10.
5	燕飞，黄南渠，金凤. 蛋白磷酸酶2A对微管相关蛋白tau的作用在阿尔茨海默病中的研究进展［J］. 遵义医科大学学报， 2020， 43（3）： 390-404.
6	SERGIENKO N M， DONNER D G， DELBRIDGE L M D， et al. Protein phosphatase 2A in the healthy and failing heart： new insights and therapeutic opportunities［J］. Cell Signal， 2022， 91： 110213.
7	MAZHAR S， TAYLOR S E， SANGODKAR J， et al. Targeting PP2A in cancer： Combination therapies［J］. Biochim Biophys Acta Mol Cell Res， 2019， 1866（1）： 51-63.
8	VAINONEN J P， MOMENY M， WESTERMARCK J. Druggable cancer phosphatases［J］. Sci Transl Med， 2021， 13（588）： eabe2967.
9	ULLAH R， YIN Q， SNELL A H， et al. RAF-MEK-ERK pathway in cancer evolution and treatment［J］. Semin Cancer Biol， 2022， 85： 123-154.
10	SANDAL P， JONG C J， MERRILL R A， et al. Protein phosphatase 2A-structure， function and role in neurodevelopmental disorders［J］. J Cell Sci， 2021， 134（13）： jcs248187.
11	YU H， ZAVERI S， SATTAR Z， et al. Protein phosphatase 2A as a therapeutic target in pulmonary diseases［J］. Medicina（Kaunas）， 2023， 59（9）： 1552.
12	FOWLE H， ZHAO Z R， GRAÑA X. PP2A holoenzymes， substrate specificity driving cellular functions and deregulation in cancer［J］. Adv Cancer Res， 2019， 144： 55-93.
13	CHO U S， XU W Q. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme［J］. Nature， 2007， 445（7123）： 53-57.
14	SANGODKAR J， FARRINGTON C C， MCCLINCH K， et al. All roads lead to PP2A： exploiting the therapeutic potential of this phosphatase［J］. FEBS J， 2016， 283（6）： 1004-1024.
15	SLUPE A M， MERRILL R A， STRACK S. Determinants for substrate specificity of protein phosphatase 2A［J］. Enzyme Res， 2011， 2011： 398751.
16	GRECH G， BALDACCHINO S， SALIBA C， et al. Deregulation of the protein phosphatase 2A， PP2A in cancer： complexity and therapeutic options［J］. Tumour Biol， 2016， 37（9）： 11691-11700.
17	EICHHORN P J A， CREYGHTON M P， BERNARDS R. Protein phosphatase 2A regulatory subunits and cancer［J］. Biochim Biophys Acta， 2009， 1795（1）： 1-15.
18	PERIS I， ROMERO-MURILLO S， VICENTE C， et al. Regulation and role of the PP2A-B56 holoenzyme family in cancer［J］. Biochim Biophys Acta Rev Cancer， 2023， 1878（5）： 188953.
19	FÉLIX M A， COHEN P， KARSENTI E. Cdc2 H1 kinase is negatively regulated by a type 2A phosphatase in the Xenopus early embryonic cell cycle： evidence from the effects of okadaic acid［J］. EMBO J， 1990， 9（3）： 675-683.
20	GOGUET-RUBIO P， AMIN P， AWAL S， et al. PP2A-B55 holoenzyme regulation and cancer［J］. Biomolecules， 2020， 10（11）： 1586.
21	SABLINA A A， HECTOR M， COLPAERT N， et al. Identification of PP2A complexes and pathways involved in cell transformation［J］. Cancer Res， 2010， 70（24）： 10474-10484.
22	TOMIYAMA A， KOBAYASHI T， MORI K， et al. Protein phosphatases-a touchy enemy in the battle against glioblastomas： a review［J］. Cancers （Basel）， 2019， 11（2）： 241.
23	DEDOBBELEER M， WILLEMS E， FREEMAN S， et al. Phosphatases and solid tumors： focus on glioblastoma initiation， progression and recurrences［J］. Biochem J， 2017， 474（17）： 2903-2924.
24	KASHANI E， VASSELLA E. Pleiotropy of PP2A phosphatases in cancer with a focus on glioblastoma IDH wildtype［J］. Cancers （Basel）， 2022， 14（21）： 5227.
25	CLARK A R， OHLMEYER M. Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration［J］. Pharmacol Ther， 2019， 201： 181-201.
26	GADEK J E， KLEIN H G， HOLLAND P V， et al. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects［J］. J Clin Invest， 1981， 68（5）： 1158-1165.
27	RUEDIGER R， RUIZ J， WALTER G. Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice［J］. Mol Cell Biol， 2011， 31（18）： 3832-3844.
28	GUO S， YANG J， WU M， et al. Clinical value screening， prognostic significance and key pathway identification of miR-204-5p in endometrial carcinoma： a study based on the Cancer Genome Atlas （TCGA）， and bioinformatics analysis［J］. Pathol Res Pract， 2019， 215（5）： 1003-1011.
29	REMMERIE M， JANSSENS V. PP2A： a promising biomarker and therapeutic target in endometrial cancer［J］. Front Oncol， 2019， 9： 462.
30	GIBSON W J， HOIVIK E A， HALLE M K， et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis［J］. Nat Genet， 2016， 48（8）： 848-855.
31	WANDZIOCH E， PUSEY M， WERDA A， et al. PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells［J］. Cancer Res， 2014， 74（16）： 4295-4305.
32	LIANG X J， BAO X F， CHEN G L. SET protein in cancer： a potential therapeutic target［J］. Mini Rev Med Chem， 2021， 21（16）： 2290-2299.
33	ZHANG W P， CAI J X， CHEN S Y， et al. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway［J］. Mol Med Rep， 2015， 12（1）： 1506-1514.
34	YAZDI A， GHASEMI-KASMAN M， JAVAN M. Possible regenerative effects of fingolimod （FTY720） in multiple sclerosis disease： an overview on remyelination process［J］. J Neurosci Res， 2020， 98（3）： 524-536.
35	DE PALMA R M， PARNHAM S R， LI Y T， et al. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction［J］. FASEB J， 2019， 33（6）： 7647-7666.
36	O’CONNOR C M， PERL A， LEONARD D， et al. Therapeutic targeting of PP2A［J］. Int J Biochem Cell Biol， 2018， 96： 182-193.
37	DE P， CARLSON J H， LEYLAND-JONES B， et al. Role of “oncogenic nexus” of CIP2A in breast oncogenesis： how does it work？［J］. Am J Cancer Res， 2015， 5（9）： 2872-2891.
38	VAARALA M H， VÄISÄNEN M R， RISTIMÄKI A. CIP2A expression is increased in prostate cancer［J］. J Exp Clin Cancer Res， 2010， 29（1）： 136.
39	JUNTTILA M R， PUUSTINEN P， NIEMELÄ M， et al. CIP2A inhibits PP2A in human malignancies［J］. Cell， 2007， 130（1）： 51-62.
40	PAVIC K， GUPTA N， OMELLA J D， et al. Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A［J］. Nat Commun， 2023， 14： 1143.
41	MANNAVA S， OMILIAN A R， WAWRZYNIAK J A， et al. PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells［J］. Oncogene， 2012， 31（12）： 1484-1492.
42	LI Y T， BALAKRISHNAN V K， ROWSE M， et al. Coupling to short linear motifs creates versatile PME-1 activities in PP2A holoenzyme demethylation and inhibition［J］. eLife， 2022， 11： e79736.
43	XING Y N， LI Z， CHEN Y， et al. Structural mechanism of demethylation and inactivation of protein phosphatase 2A［J］. Cell， 2008， 133（1）： 154-163.
44	JACKSON J B， PALLAS D C. Circumventing cellular control of PP2A by methylation promotes transformation in an Akt-dependent manner［J］. Neoplasia， 2012， 14（7）： 585-599.
45	GUFFENS L， DERUA R， JANSSENS V. PME-1 sensitizes glioblastoma cells to oxidative stress-induced cell death by attenuating PP2A-B55α-mediated inactivation of MAPKAPK2-RIPK1 signaling［J］. Cell Death Discov， 2023， 9（1）： 265.
46	BI L， XIE C L， YAO M， et al. The histone chaperone complex FACT promotes proliferative switch of G₀ cancer cells［J］. Int J Cancer， 2019， 145（1）： 164-178.
47	COLIAT P， RAMOLU L， JÉGU J， et al. Constitutive or induced HIF-2 addiction is involved in resistance to anti-EGFR treatment and radiation therapy in HNSCC［J］. Cancers （Basel）， 2019， 11（10）： 1607.
48	CHUNG V， MANSFIELD A S， BRAITEH F， et al. Safety， tolerability， and preliminary activity of LB-100， an inhibitor of protein phosphatase 2A， in patients with relapsed solid tumors： an open-label， dose escalation， first-in-human， phase I trial［J］. Clin Cancer Res， 2017， 23（13）： 3277-3284.
49	LEI X， MA N， DU L H， et al. PP2A and tumor radiotherapy［J］. Hereditas， 2020， 157（1）： 36.
50	ZHANG D M， FU M J， LI L Y， et al. PKC-δ attenuates the cancer stem cell among squamous cell carcinoma cells through down-regulating p63［J］. Pathol Res Pract， 2017， 213（9）： 1119-1124.

[1]	Gengfei CAO, SHAYA·Mahati,Junpeng GU,Weizheng JI, ASIHAER·Hasimu,Weixin REN. Differences in immune microenvironment between DEB-TACE and c-TACE in treatment of hepatocellular carcinoma and mechanism of TRADD-mediated Th17 differentiation [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 764-780.
[2]	Changfeng LIU,Guangjun JIN,Yonggang WANG. Primary renal angiosarcoma with multiple abdominal haemorrhages： A case repert and literature review [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 821-827.
[3]	Qiuping SU,Lei XING,Wei ZHANG,Shan JIANG,Yangyang ZHAO,Fangfang CHEN. Research progress in anti-tumor mechanism of berberine and application of its novel nano-delivery system in tumor therapy [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 863-871.
[4]	Yang YU,Sheyu YE,Kexin WEI,Zhicheng WANG. Research progress in formation mechanism of tumor radioresistance and inhibitory effect of low-dose radiotherapy combination with novel sensitization strategies on tumor radioresistance [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 872-880.
[5]	Xiqian ZHANG,Zhibo DANG,Yunan DU,Pei WU,Hang XIE,Gaofeng TAN. Inhibitory effect of Chaiqi Yigan formula on malignant biological behaviors of liver cancer HepG2 cells by regulating macrophage polarization [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 398-409.
[6]	Yu ZHAO,Xiaoshuang HE,Xiaoyin DONG,Fengyi GAO,Jiageng HE. Regulatory effect of lncRNA urothelial carcinoembryonic antigen 1 on anoikis in human gastrointestinal stromal tumor cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 429-439.
[7]	Shuangji LI,He SHI,Yiwen QIN,Xiang LI,Yuyang LI,Weiwei LIU,Jia LI. Desmoplastic fibroma of mandible: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 246-251.
[8]	Luyao WANG,Chenxi ZHAO,Jincheng DU,Linlin LIU. Research progress in effect of Toll-like receptor 7/8 on occurrence and development of tumor [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 264-271.
[9]	Hongfei WANG,Guangquan LI. Research progress in relationship between deubiquitinase OTUB2 and occurrence and development of tumor [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1763-1770.
[10]	Rongmian YAN,Xinting SUN,Xin GUAN,Yu CHENG,Liying HAN. Effects of KLK5 overexpression on growth of subcutaneous xenograft tumor and cisplatin sensitivity in nude mice [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1194-1203.
[11]	Yingran YANG,Jing WANG,Youzheng QIU,Shanshan ZHANG,Na LI,Wei SHEN,Ying CHEN,Ning WANG. Inhibitory effect of IFN-γ on proliferation of neuroblastoma cells and clinical significance of SULT2B1 protein expression in neuroblastoma tissue [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1267-1273.
[12]	Di QIN,Lihong HUAGN,Qingshuang ZHENG,Jingjing SUN,Weimin XU. Analysis on correlation between serum pro-inflammatory cytokines and muscle mass in elderly patients with sarcopenic obesity and diabetes [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1293-1302.
[13]	Ming CHEN,Qinghua LUO,Hongguang JIN,Liang HAN. Atypical lipomatous tumor of left lower limb: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1384-1389.
[14]	Jia YANG,Lingling TONG,Jinshu MA,Huafeng GENG. Misdiagnosis of ovarian sclerosing stromal tumor as malignant tumor: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1115-1120.
[15]	Hongjie LI,Maozhuo LAN,Xiao WANG,Ranran FENG,Yanyan TAO,Jiaqing LIU,Haibai SUN. Effect of BTK inhibitor BGB-3111 combined with bortezomib on apoptosis of human multiple myeloma cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 599-609.

Research progress in relationship between protein phosphatase 2A and occurrence and development of tumor

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 50

Related Articles 15

Metrics

Comments

Recommended 10